Noah Associates Incorporated

Noah Associates Incorporated was paid $10.61M by Medicaid between Jan 2018 and Oct 2023, across 87 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 29% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Wisconsin

Rank by total paid#6 of 75

Median peer was paid$106K

This provider vs. median100×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	10,347	$1.07M
2019	24,887	$1.58M
2020	51,220	$2.04M
2021	30,772	$1.96M
2022	40,836	$2.28M
2023	38,350	$1.68M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	29%	30,685	10,973	$3.05M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	25%	79,449	32,491	$2.65M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	21%	37,207	17,777	$2.23M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	19%	14,568	8,149	$2.02M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	3.3%	9,028	4,580	$348K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	1.4%	2,303	1,398	$149K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	525	360	$58K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,328	641	$18K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	925	653	$15K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	827	661	$5K
86769		<1%	213	193	$5K
87481		<1%	309	248	$5K

75 more codes

87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	18	$5K
80061	Lipid panel	<1%	1,030	$3K
83719		<1%	960	$3K
84481		<1%	714	$2K
80053	Comprehensive metabolic panel	<1%	1,151	$2K
87653		<1%	335	$2K
82607		<1%	746	$2K
83698		<1%	178	$2K
83036	Hemoglobin; glycosylated (A1C)	<1%	926	$2K
83001		<1%	602	$2K
83876		<1%	177	$2K
83002		<1%	587	$2K
84439		<1%	931	$2K
84443	Thyroid stimulating hormone (TSH)	<1%	1,024	$2K
80050	General health panel	<1%	27	$2K
82746		<1%	548	$1K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	77	$1K
84403		<1%	219	$1K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	66	$1K
82670		<1%	205	$1K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,099	$1K
82172		<1%	197	$942.60
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	52	$905.35
86038		<1%	495	$888.26
84466		<1%	281	$787.82
83090		<1%	178	$768.76
83540		<1%	540	$681.34
87529		<1%	23	$666.71
87563		<1%	45	$611.95
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	35	$587.88
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	16	$579.81
83695		<1%	159	$569.93
86140		<1%	586	$549.66
84153		<1%	162	$493.56
84402		<1%	125	$491.57
85652		<1%	516	$478.68
86431		<1%	493	$464.74
87581		<1%	21	$431.61
84550		<1%	489	$431.26
82150		<1%	405	$431.25
87486		<1%	21	$414.06
86800		<1%	150	$413.08
86376		<1%	170	$401.17
86141		<1%	88	$394.98
82627		<1%	90	$355.68
87500		<1%	59	$355.25
82728		<1%	32	$348.93
84270		<1%	90	$347.68
84154		<1%	124	$316.32
84146		<1%	90	$310.08
83735		<1%	188	$300.15
83655		<1%	26	$255.54
84202		<1%	22	$233.91
83550		<1%	191	$221.10
84702		<1%	83	$199.49
87511		<1%	23	$193.01
84144		<1%	25	$125.16
87640		<1%	34	$121.31
87641		<1%	34	$121.31
84480		<1%	42	$116.28
87086	Culture, bacterial; quantitative colony count, urine	<1%	29	$103.30
86901		<1%	253	$98.58
86900		<1%	253	$98.58
83921		<1%	19	$84.84
85651		<1%	59	$80.77
84703		<1%	39	$57.46
82552		<1%	33	$53.56
85027		<1%	14	$31.48
83721		<1%	87	$20.79
85045		<1%	53	$19.95
81001		<1%	14	$15.22
80177		<1%	15	$13.25
84478		<1%	85	$11.37
81003		<1%	15	$9.00
36415	Collection of venous blood by venipuncture	0%	57	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHANSON, JUSTIN (VICE PRESIDENT)